Theresa R. Boni
Nessuna posizione attualmente
Profilo
Theresa R.
Boni served as Vice President & Assistant General Counsel at Dicerna Pharmaceuticals, Inc. She also worked as Secretary, Senior VP-Legal & General Counsel at Surface Oncology, Inc. in 2022.
Boni received her undergraduate degree from Union College (New York) and her graduate degree from Boston University School of Law.
Precedenti posizioni note di Theresa R. Boni
Società | Posizione | Fine |
---|---|---|
SURFACE ONCOLOGY, INC. | Consigliere Generale | 01/11/2022 |
DICERNA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formazione di Theresa R. Boni
Union College (New York) | Undergraduate Degree |
Boston University School of Law | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Surface Oncology, Inc.
Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
- Borsa valori
- Insiders
- Theresa R. Boni